<DOC>
	<DOCNO>NCT01946919</DOCNO>
	<brief_summary>Cinepazide Maleate Injection widely use cerebrovascular disease china . The safety cinepazide , especially blood system , fully evaluate Chinese population . In order improve rational use cinepazide , investigator observe clinical use real world China , evaluate safety clinical benefit large Chinese population .</brief_summary>
	<brief_title>Post-Marketing Surveillance Cinepazide Maleate Injection : Real World Study</brief_title>
	<detailed_description>Cinepazide firstly approve France 1974 , formulation injection tablet . Products contain cinepazide withdrawn 1990s manufacturer lack demonstrate efficacy risk agranulocytosis European country , France , Spain , Italy . In Aisa country , re-registered Japan 2000s , injection still use China Korea . In china , Cinepazide Maleate Injection approve China Food Drug Administration ( CFDA ) 2002 , widely use cerebrovascular disease . The safety Cinepazide , especially adverse drug reaction blood system , benn fully evaluate Chinese population . In study , clinical pharmacist select hospital record clinical use adverse drug reactions/ adverse drug event injection . This real world study Cinepazide Maleate Injection 18000 patient conduct Sep. 2012 June . 2014 .</detailed_description>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Inpatient use cinepazide department neurology</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Cinepazide</keyword>
	<keyword>Adverse Drug Reaction</keyword>
	<keyword>Safety</keyword>
	<keyword>Real World Study</keyword>
</DOC>